Arch Biopartners Inc. (ACHFF)
OTCQB OTCQB Primary Summary
Arch Biopartners Inc. (ACHFF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Arch Biopartners Inc. ever had a stock split?
Arch Biopartners Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Richard Gabriel Muruve CEO | OTCQB Exchange | - ISIN |
| Canada Country | - Employees | - Last Dividend | 26 Nov 2003 Last Split | - IPO Date |
Overview
Arch Biopartners Inc., is a distinguished entity within the biopharmaceutical sector, primarily focused on the development of therapeutic drugs aimed at mitigating inflammation and tackling acute organ injuries. Operating from Toronto, Canada, alongside its subsidiaries, the company is at the forefront of addressing some of the most challenging medical conditions through its innovative drug development programs. With a keen emphasis on progressing their lead drug candidate, LSALT Peptide, through Phase 2 clinical trials, Arch Biopartners Inc. is pioneering the treatment of dipeptidase-1 mediated organ inflammation, a critical mediator of organ distress in the lungs, liver, and kidneys.
Products and Services
- LSALT Peptide
- LSALT Peptide stands as the flagship drug candidate of Arch Biopartners Inc., currently in Phase 2 clinical trials. This innovative therapeutic is being developed to address organ inflammation, primarily targeting the lungs, liver, and kidneys, by inhibiting dipeptidase-1. The potential of LSALT Peptide to mitigate organ distress offers a promising avenue for treating conditions characterized by severe inflammation.
- AB569
- AB569 marks another pivotal development within the company’s portfolio, aimed at combating antibiotic-resistant bacterial infections. This novel therapy is not only positioned to offer new hope in treating stubborn bacterial infections but also has applications in wound treatment. The dual functionality of AB569 underscores Arch Biopartners Inc.’s commitment to addressing both infectious diseases and their complications through innovative therapeutic approaches.
- Borg
- Diverging from the company's primary focus on drug development, Borg represents a unique product engineered to interface between peptides and solid surfaces, particularly targeting metal corrosion. This technological innovation not only highlights the versatility of Arch Biopartners Inc.’s research and development endeavours but also opens up new possibilities in materials science, offering solutions to extend the lifespan and reliability of metal components in various industrial applications.
